Tower View Wealth Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.17M Sell
4,660
-1,241
-21% -$267K 0.52% 45
2026
Q1
$1.28M Buy
5,901
+974
+20% +$216K 0.66% 42
2025
Q4
$1.13M Buy
4,927
+4,024
+446% +$917K 0.56% 43
2025
Q3
$209K Sell
903
-115
-11% -$23.4K 0.11% 53
2025
Q2
$189K Buy
1,018
+9
+0.9% +$1.67K 0.1% 63
2025
Q1
$211K Sell
1,009
-8
-0.8% -$1.55K 0.12% 50
2024
Q4
$181K Buy
1,017
+9
+0.9% +$1.66K 0.1% 56
2024
Q3
$199K Buy
1,008
+4
+0.4% +$747 0.11% 55
2024
Q2
$172K Buy
1,004
+4
+0.4% +$663 0.1% 55
2024
Q1
$182K Sell
1,000
-273
-21% -$47K 0.11% 60
2023
Q4
$197K Sell
1,273
-114
-8% -$16.6K 0.12% 54
2023
Q3
$207K Buy
1,387
+541
+64% +$79.4K 0.15% 54
2023
Q2
$114K Buy
846
+197
+30% +$28.9K 0.08% 62
2023
Q1
$103K Sell
649
-11
-2% -$1.68K 0.07% 67
2022
Q4
$107K Sell
660
-23
-3% -$3.53K 0.07% 67
2022
Q3
$92K Buy
683
+84
+14% +$12.1K 0.07% 69
2022
Q2
$92K Hold
599
0.07% 70
2022
Q1
$97K Buy
599
+1
+0.2% +$145 0.05% 89
2021
Q4
$81K Buy
598
+1
+0.2% +$118 0.04% 90
2021
Q3
$64K Buy
597
+432
+262% +$49.4K 0.04% 95
2021
Q2
$19K Sell
165
-23
-12% -$2.59K 0.01% 109
2021
Q1
$20K Sell
188
-230
-55% -$24.6K 0.01% 116
2020
Q4
$45K Buy
418
+134
+47% +$12.9K 0.03% 104
2020
Q3
$25K Buy
284
+3
+1% +$282 0.02% 96
2020
Q2
$28K Buy
281
+4
+1% +$352 0.02% 88
2020
Q1
$21K Buy
277
+3
+1% +$256 0.02% 84
2019
Q4
$24K Buy
274
+3
+1% +$249 0.02% 98
2019
Q3
$20K Buy
271
+5
+2% +$343 0.02% 100
2019
Q2
$19K Buy
266
+3
+1% +$236 0.02% 98
2019
Q1
$21K Buy
263
+4
+2% +$327 0.02% 97
2018
Q4
$24K Buy
259
+3
+1% +$264 0.02% 95
2018
Q3
$24K Sell
256
-46
-15% -$4.36K 0.02% 111
2018
Q2
$28K Buy
302
+3
+1% +$293 0.03% 103
2018
Q1
$28K Buy
299
+1
+0.3% +$110 0.03% 102
2017
Q4
$29K Buy
+298
New +$28.1K 0.03% 106

Other funds holding ABBV

Tower View Wealth Management's ABBV Position: Q2 2026 in Review

Tower View Wealth Management reduced its AbbVie (ABBV) stake by 21% in Q2 2026, selling an estimated $267K and leaving 4,660 shares worth $1.17M. The position accounts for 0.52% of the portfolio, ranked #45.

Tower View Wealth Management first reported a position in ABBV in Q4 2017 and has held it in 35 quarters since. The position peaked at $1.28M in Q1 2026. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Tower View Wealth Management held 4,660 shares of AbbVie worth $1.17M as of Q2 2026.
  • Tower View Wealth Management sold 1,241 AbbVie shares in Q2 2026, an estimated $267K.
  • AbbVie made up 0.52% of Tower View Wealth Management's portfolio in Q2 2026, its #45 holding.
  • Tower View Wealth Management first reported a position in AbbVie in Q4 2017 and has held it in 35 quarters since.
  • Tower View Wealth Management's AbbVie position peaked at $1.28M in Q1 2026.
  • 4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Tower View Wealth Management's 13F filing for Q2 2026, filed 24 Jul 2026.